What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Pier Luigi Zinzani focuses on Internal medicine, Lymphoma, Surgery, Gastroenterology and Chemotherapy.
In most of his Internal medicine studies, his work intersects topics such as Oncology.
His study in Oncology is interdisciplinary in nature, drawing from both Progressive disease, Clinical trial, Etoposide, Brentuximab vedotin and Hodgkin's lymphoma.
He has researched Lymphoma in several fields, including Peripheral T-cell lymphoma and Positron emission tomography, Nuclear medicine.
The concepts of his Gastroenterology study are interwoven with issues in Phases of clinical research, T-cell lymphoma, Neutropenia, Survival analysis and Fludarabine.
Pier Luigi Zinzani interconnects CHOP, Maintenance therapy, Diffuse large B-cell lymphoma, Follicular lymphoma and CD20 in the investigation of issues within Rituximab.
His most cited work include:
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group (1582 citations)
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (1433 citations)
- Follicular lymphoma international prognostic index. (1297 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Lymphoma, Surgery and Gastroenterology.
His is doing research in Rituximab, Chemotherapy, Refractory, Regimen and Neutropenia, both of which are found in Internal medicine.
The various areas that Pier Luigi Zinzani examines in his Chemotherapy study include Stage and Survival rate.
His Oncology research incorporates themes from Brentuximab vedotin, Follicular lymphoma, Immunology and Phases of clinical research.
His studies in Lymphoma integrate themes in fields like Positron emission tomography, Radiation therapy, Radiology and Nuclear medicine.
The Gastroenterology study combines topics in areas such as Hairy cell leukemia, Tolerability and Toxicity.
He most often published in these fields:
- Internal medicine (63.12%)
- Oncology (36.77%)
- Lymphoma (34.73%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (63.12%)
- Oncology (36.77%)
- Lymphoma (34.73%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Refractory.
Internal medicine is frequently linked to Gastroenterology in his study.
The study incorporates disciplines such as Regimen and Tolerability in addition to Gastroenterology.
His work in Oncology tackles topics such as Diffuse large B-cell lymphoma which are related to areas like Lenalidomide and Cancer.
His Lymphoma study combines topics in areas such as Progressive disease, Biopsy, Clinical trial and Progression-free survival.
His research integrates issues of Pembrolizumab, Peripheral T-cell lymphoma, Chemotherapy and Transplantation in his study of Brentuximab vedotin.
Between 2018 and 2021, his most popular works were:
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma (125 citations)
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 (79 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Lymphoma, In patient and Refractory.
Brentuximab vedotin, Follicular lymphoma, Neutropenia, Phases of clinical research and Adverse effect are among the areas of Internal medicine where the researcher is concentrating his efforts.
His research in Follicular lymphoma intersects with topics in Gastroenterology and Rituximab.
His biological study spans a wide range of topics, including Open label, Diffuse large B-cell lymphoma, Hodgkin lymphoma, Relapsed refractory and Poor prognosis.
His Lymphoma research is multidisciplinary, incorporating perspectives in T cell, Hematology, Cyclophosphamide, Regulation of gene expression and Nivolumab.
His Refractory study integrates concerns from other disciplines, such as Pembrolizumab and Primary Mediastinal Large B-Cell Lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
